Replies to post #96504 on Biotech Values

[DewDiligence]

PFE reports positive Inspra data in CHF:

http://finance.yahoo.com/news/Adding-INSPRA-eplerenone-to-prnews-1320656543.html?x=0&.v=2

The EMPHASIS-HF trial demonstrated a statistically significant 37% relative risk reduction for the eplerenone group (p<0.0001) compared to placebo in the primary composite endpoint of death from CV causes or HF hospitalization. There were also statistically significant reductions in other secondary endpoints of all-cause mortality (24%; p=0.008), CV mortality (24%; p=0.012), all-cause hospitalization (23%, p<0.0001) and HF hospitalization (42%; p<0.0001).

PFE had announced that the trial hit its primary endpoint in May 2010 (#msg-50690157) but withheld the details until the AHA conference taking place this weekend.

Despite the stellar clinical data, Inspra is an almost meaningless drug for PFE insofar as generics have been available in the US since mid 2008. The drug was developed by the GD Searle division of the original Monsanto, which became part of Pharmacia in 2000 and was merged into PFE in 2003.